FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated with Schizophrenia - Pharmaceutical Executive
FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated with Schizophrenia Pharmaceutical Executive
NewsKrez Editorial DeskNovember 16, 2026 • 11:45 AM UTC
3 min read2 views
FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated with Schizophrenia Pharmaceutical Executive
Regulatory Verification & Source Attribution
This intelligence report was compiled and verified by the NewsKrez Editorial & Regulatory Intelligence Desk.
Sponsored Intelligence
Medical Device Software Compliance
Automated 21 CFR Part 820 & ISO 13485 Verification
Explore Solution →